In the past week, NLSP stock has gone down by -0.23%, with a monthly decline of -24.26% and a quarterly plunge of -71.65%. The volatility ratio for the week is 14.27%, and the volatility levels for the last 30 days are 12.41% for NLS Pharmaceutics Ltd The simple moving average for the past 20 days is -10.37% for NLSP’s stock, with a -76.88% simple moving average for the past 200 days.
Is It Worth Investing in NLS Pharmaceutics Ltd (NASDAQ: NLSP) Right Now?
Additionally, the 36-month beta value for NLSP is -0.69. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NLSP is 21.84M and currently, short sellers hold a 0.34% ratio of that float. The average trading volume of NLSP on April 26, 2024 was 578.89K shares.
NLSP) stock’s latest price update
NLS Pharmaceutics Ltd (NASDAQ: NLSP)’s stock price has gone rise by 5.92 in comparison to its previous close of 0.12, however, the company has experienced a -0.23% decrease in its stock price over the last five trading days. InvestorPlace reported 2023-12-04 that NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company’s shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an exclusive option to license in-license Aexon Labs’ Dual Orexin Receptor Agonists platform.
NLSP Trading at -49.73% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.35% of loss for the given period.
Volatility was left at 12.41%, however, over the last 30 days, the volatility rate increased by 14.27%, as shares sank -19.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -71.22% lower at present.
During the last 5 trading sessions, NLSP fell by -0.23%, which changed the moving average for the period of 200-days by -85.29% in comparison to the 20-day moving average, which settled at $0.1461. In addition, NLS Pharmaceutics Ltd saw -77.56% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NLSP
The total capital return value is set at 8.84.
Currently, EBITDA for the company is -15.47 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.58.
Conclusion
In conclusion, NLS Pharmaceutics Ltd (NLSP) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
